TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18221474

Group type: EXPERIMENTAL
Intervention: Simultaneous intramuscular influenza and pneumococcal heptavalent conjugate vaccinations (IV + PV)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Influenza and placebo vaccinations (IV + plac)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Control hepatitis B and placebo vaccinations (HepB + plac)
Number of subjects: 579
Study: 16773418

Group type: EXPERIMENTAL
Intervention: Ayurvedic polyherbal preparation 'Shathavaryadi Yoga (NS001)'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral cyclophosphamide
Number of subjects: 0
Study: 12742282

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day, n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Statin therapy (Atorvastatin and Simvastatin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30
Study: 10805693

Group type: COMPARATOR
Intervention: Electrical stimulation of the sural nerve at a nonnociceptive intensity during early and late swing phases while walking on a treadmill.
Number of subjects: 2
Study: 8827017

Group type: EXPERIMENTAL
Intervention: Prechemotherapy G‐CSF (administered subcutaneously twice per day for 5 days at a dose of 5 micrograms/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Postchemotherapy G‐CSF (administered subcutaneously once per day for 7 days at a dose of 5 micrograms/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prechemotherapy G‐CSF
Number of subjects: 36

Group type: COMPARATOR
Intervention: Postchemotherapy G‐CSF
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 36
Study: 1462413

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g at bedtime
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 3892050

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy with positive skin test conversion
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy with negative skin test
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy with previously positive skin test
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guerin
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy in high-risk patients
Number of subjects: 122
Study: 30920684

Group type: EXPERIMENTAL
Intervention: Group cognitive processing therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group present-centered therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (nonhazardous drinkers)
Number of subjects: 108
Study: 29081351

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) plus pill placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline (SERT) plus Enhanced Medication Management (EMM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment (PE/SERT)
Number of subjects: 0
Study: 27560289

Group type: EXPERIMENTAL
Intervention: Monophasic monodensified hyaluronic acid (MMHA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Biphasic nonanimal stabilized hyaluronic acid (BHA)
Number of subjects: 49
Study: 24343370

Group type: EXPERIMENTAL
Intervention: Ventilated on CPB (VG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-ventilated CPB group (NVG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 23700945

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous omega-3 PUFAs (Omegaven 10%) infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline solution infusion (control group)
Number of subjects: 40
Study: 20973604

Group type: EXPERIMENTAL
Intervention: Verbal working memory training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18072874

Group type: EXPERIMENTAL
Intervention: High-impact jumping exercises
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonimpact stretching activities
Number of subjects: 57
Study: 16168733

Group type: EXPERIMENTAL
Intervention: Generation of Hypotheses test (Left Lateral subgroup)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recognition of the Rule test (Left Lateral subgroup)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Generation of Hypotheses test (Right Lateral subgroup)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recognition of the Rule test (Right Lateral subgroup)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Generation of Hypotheses test (Medial subgroup)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recognition of the Rule test (Medial subgroup)
Number of subjects: 46
Study: 12973173

Group type: EXPERIMENTAL
Intervention: GIK solution (30% glucose in water with insulin 50 U/L, and KCl 40 mM/L) at 1.5 mL/kg/hr for 24 hrs
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10696980

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b, colchicine, and benzathine penicillin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Colchicine and benzathine penicillin alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: No interferon therapy
Number of subjects: 135
Study: 9024895

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1891078

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study: 3519241

Group type: EXPERIMENTAL
Intervention: Felodipine in addition to hydrochlorothiazide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31260028

Group type: EXPERIMENTAL
Intervention: Culturally tailored 12-minute stroke films
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (stroke education pamphlets)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Culturally tailored 12-minute stroke films (low-education subgroup)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (low-education subgroup)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Culturally tailored 12-minute stroke films (high-education subgroup)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care (high-education subgroup)
Number of subjects: 312
Study: 29863386

Group type: EXPERIMENTAL
Intervention: consumed-sugar/told-sugar
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: consumed-sugar/told-no-sugar
Number of subjects: 105

Group type: COMPARATOR
Intervention: consumed-no-sugar/told-sugar
Number of subjects: 105

Group type: COMPARATOR
Intervention: consumed-no-sugar/told-no-sugar
Number of subjects: 105
Study: 26184035

Group type: COMPARATOR
Intervention: Standard shoes + ankle-foot orthosis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rocker shoes + ankle-foot orthosis
Number of subjects: 30
Study: 23511293

Group type: EXPERIMENTAL
Intervention: Gabapentin (dosage: 300 mg TID, 600 mg TID, 800 mg TID, 1200 mg TID)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 53
Study: 22541659

Group type: EXPERIMENTAL
Intervention: DSAEK
Number of subjects: 118

Group type: COMPARATOR
Intervention: PK
Number of subjects: 118

Group type: COMPARATOR
Intervention: FS-DSEK
Number of subjects: 118

Group type: COMPARATOR
Intervention: DSAEK vs PK
Number of subjects: 118
Study: 20302988

Group type: EXPERIMENTAL
Intervention: Depression at 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Depression at 2 years
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anxiety at 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anxiety at 2 years
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictors of depression at 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictors of anxiety at 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictors of depression at 2 years
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Predictors of anxiety at 2 years
Number of subjects: 100
Study: 22423114

Group type: EXPERIMENTAL
Intervention: Whole-brain multivariate pattern-based analysis (MVPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Univariate adaptation-fMRI paradigm
Number of subjects: 0
Study: 15953498

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12426230

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg loading dose and 10 mg/hour until Day 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone withdrawal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9514066

Group type: EXPERIMENTAL
Intervention: Video Before
Number of subjects: 128

Group type: COMPARATOR
Intervention: Video After
Number of subjects: 128
Study: 7708993

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2651508

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 782804

Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 31405764

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily before surgery
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 28057360

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg (weeks 0 and 4, then every 8 weeks)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks through week 47)
Number of subjects: 837
Study: 26174611

Group type: EXPERIMENTAL
Intervention: AZD0837 (oral direct thrombin inhibitor)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 601
Study: 23428337

Group type: EXPERIMENTAL
Intervention: Lu AA21004 (2.5, 10, or 60 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lu AA21004 (30 mg)
Number of subjects: 11
Study: 21526919

Group type: EXPERIMENTAL
Intervention: Routine upfront abciximab administration (bolus followed by 12-hour infusion)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard therapy (selective abciximab use during intervention)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Routine upfront abciximab administration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 80
Study: 17962243

Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: NNS
Number of subjects: 99
Study: 16243440

Group type: EXPERIMENTAL
Intervention: Intravenous amifostine 300 mg/m2
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 12527537

Group type: COMPARATOR
Intervention: Standard Cognitive-Behavior Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Cognitive-Behavior Therapy (ECBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 10638560

Group type: EXPERIMENTAL
Intervention: Pantoprazole (PANT) 40 mg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Ranitidine (RAN) 300 mg
Number of subjects: 222
Study: 8785033

Group type: EXPERIMENTAL
Intervention: Polyamide membrane hemodialysis for 4 months
Number of subjects: 6
Study: 1548988

Group type: EXPERIMENTAL
Intervention: Upright water-based exercise at 60% of maximal treadmill heart rate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upright water-based exercise at 70% of maximal treadmill heart rate
Number of subjects: 10
Study: 10272531

Group type: EXPERIMENTAL
Intervention: Postcard/telephone reminder system
Number of subjects: 102
Study: 30231915

Group type: EXPERIMENTAL
Intervention: Endovascular Acute Stroke Intervention (EASI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombectomy trials (comparison)
Number of subjects: 0
Study: 27894358

Group type: EXPERIMENTAL
Intervention: Neurofeedback-assisted, technology-supported mindfulness training (N-tsMT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Daily online math training (control condition)
Number of subjects: 26
Study: 24625519

Group type: EXPERIMENTAL
Intervention: PICC line inserted through the axillary vein
Number of subjects: 62

Group type: COMPARATOR
Intervention: PICC line inserted through other sites
Number of subjects: 62
Study: 21420840

Group type: EXPERIMENTAL
Intervention: High fat meal (HF): 37% carbohydrate, 52% fat
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderate fat meal (MF): 61% carbohydrate, 27% fat
Number of subjects: 10
Study: 21422713

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d) and Vitamin C (500 mg/d) supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 18695096

Group type: EXPERIMENTAL
Intervention: Atropine eyedrops for 6 months
Number of subjects: 419

Group type: COMPARATOR
Intervention: Patching for 6 months
Number of subjects: 419
Study: 15871318

Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured keratinocytes
Number of subjects: 4

Group type: COMPARATOR
Intervention: Petrolatum gauze (control)
Number of subjects: 4
Study: 12135218

Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy and endometrial biopsy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Endometrial biopsy alone
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Number of subjects: 370
Study: 10539870

Group type: EXPERIMENTAL
Intervention: 600 mg/d Zithromax for 3 days then 600 mg/wk for 11 additional weeks
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3500
Study: 8580577

Group type: EXPERIMENTAL
Intervention: Small-peptide enteral diet
Number of subjects: 41

Group type: COMPARATOR
Intervention: Whole-protein diet
Number of subjects: 41
Study: 2317751

Group type: EXPERIMENTAL
Intervention: Simultaneous combined technique therapy (SIM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sequential combined technique therapy (SEQ)
Number of subjects: 48
Study: 30526388

Group type: EXPERIMENTAL
Intervention: Acacia bark extract tablets
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29191951

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: CPAP usage >4 h·night−1
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Good CPAP adherence with ESS >10 at baseline
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Lower average nightly CPAP use
Number of subjects: 1105

Group type: EXPERIMENTAL
Intervention: Presence of sleepiness at baseline
Number of subjects: 1105
Study: 25599884

Group type: EXPERIMENTAL
Intervention: Boomerang™ wire with manual compression (MC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Manual compression (MC) alone
Number of subjects: 450
Study: 24862623

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS group)
Number of subjects: 408

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS group)
Number of subjects: 408
Study: 22622962

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (choline fenofibrate) 135 mg once daily
Number of subjects: 682

Group type: COMPARATOR
Intervention: Placebo plus atorvastatin treatment
Number of subjects: 682
Study: 19258485

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions with behavioral components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions with behavioral and/or cognitive components
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17566199

Group type: EXPERIMENTAL
Intervention: Differential-pressure valves
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Delta valves
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Orbis-Sigma valves
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Younger age at shunt insertion (42 days) compared to older age (134 days)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Hydrocephalus secondary to infection, head injury, or aqueductal stenosis
Number of subjects: 737
Study: 15863647

Group type: COMPARATOR
Intervention: Serum TIMP-1 concentration in stable COPD patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Serum TIMP-1 concentration during disease exacerbation in COPD patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Molar ratio of MMP-9 to TIMP-1 in COPD patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Correlation of serum TIMP-1 concentration with forced expiratory volume in one second/forced vital capacity in COPD patients
Number of subjects: 72
Study: 14964594

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapies
Number of subjects: 0
Study: 9285657

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillators (ICDs)
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Drug therapy (amiodarone or sotalol)
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Registry patients (nonrandomized)
Number of subjects: 1117
Study: 8174890

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 3453292

Group type: EXPERIMENTAL
Intervention: Sotalol hydrochloride 80 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30144304

Group type: EXPERIMENTAL
Intervention: Budesonide (BD) 256 μg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Montelukast (MNT) 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Half-dose Budesonide (hBD) 128 μg + Montelukast (MNT)
Number of subjects: 100
Study: 26523526

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 28
Study: 25526439

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 20 mg/kg/day for 2 years, then escalated to 30 mg/kg/day during extension study.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 30 mg/kg/day, then decreased to 26 mg/kg/day (range 19.5-31.2).
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy.
Number of subjects: 28
Study: 22652314

Group type: EXPERIMENTAL
Intervention: Primary Balloon Angioplasty (PTA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cryoplasty (CRYO)
Number of subjects: 40
Study: 20527138

Group type: EXPERIMENTAL
Intervention: Onion extract cream with Centella asiatica and hyaluronic acid applied twice daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control) applied to the contralateral side
Number of subjects: 0
Study: 18538305

Group type: EXPERIMENTAL
Intervention: Attentional bias training (Group T) for 7 days using the dot‐probe paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attentional bias training (Group T)
Number of subjects: 0
Study: 16043680

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 microg/d or 800 IU for 2 years, then increased to 50 microg/d or 2000 IU for 1 additional year)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 15228673

Group type: EXPERIMENTAL
Intervention: rhG‐CSF 75 micro g per day s.c. for 5 ‐ 7 days, additional 3 ‐ 5 days according to leukopenia during radiotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no rhG‐CSF)
Number of subjects: 100
Study: 10685532

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 100

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 100
Study: 9113582

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine hydrochloride plus 0.1 mL subconjunctival lignocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard peribulbar anesthesia
Number of subjects: 50
Study: 8402801

Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium lactate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Toothpaste containing calcium lactate plus sodium lauryl sulphate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 60
Study: 3519191

Group type: EXPERIMENTAL
Intervention: Sclerotherapy with the rigid Negus oesophagoscope using general anaesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined paravariceal and intravariceal sclerotherapy technique using a fibreoptic endoscope without anaesthesia
Number of subjects: 0
Study: 3257288

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 15 mg/kg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 15 mg/kg/day for 10 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 15 mg/kg/day for 28 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 35
Study: 31777949

Group type: EXPERIMENTAL
Intervention: 5 mg UPA per day for 5 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31857893

Group type: EXPERIMENTAL
Intervention: Low-fibre refined diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fibre diet with intact cellular structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fibre diet with disrupted cellular structures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28335012

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion for working memory improvement (4 sessions of 1 hour each)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Active control group (no hypnotic suggestion)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion for working memory improvement
Number of subjects: 27